Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant

2011 ◽  
Vol 58 (3) ◽  
pp. 459-461 ◽  
Author(s):  
Denise K. Bonney ◽  
Ei E. Htwe ◽  
Andrew Turner ◽  
Anna Kelsey ◽  
Abdu Shabani ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Lymphoproliferative Disease ◽  
Sustained Response ◽  
Haematopoietic Stem Cell ◽  
Cell Transplant ◽  
Post Transplant ◽  
The Central Nervous System

scholarly journals HLA-mismatched CD34-selected stem cell transplant complicated by HHV-6 reactivation in the central nervous system

2000 ◽  
Vol 25 (7) ◽  
pp. 787-790 ◽  
Author(s):  
Y Kawano ◽  
T Miyazaki ◽  
T Watanabe ◽  
A Suzue ◽  
S Kan-nuki ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
The Central Nervous System

scholarly journals Biomaterial Strategies to Bolster Neural Stem Cell-Mediated Repair of the Central Nervous System

2021 ◽  
pp. 1-15
Author(s):  
Giancarlo Tejeda ◽  
Andrew J. Ciciriello ◽  
Courtney M. Dumont
Keyword(s):  
Stem Cells ◽  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Transplant Survival ◽  
The Central Nervous System

Stem cell therapies have the potential to not only repair, but to regenerate tissue of the central nervous system (CNS). Recent studies demonstrate that transplanted stem cells can differentiate into neurons and integrate with the intact circuitry after traumatic injury. Unfortunately, the positive findings described in rodent models have not been replicated in clinical trials, where the burden to maintain the cell viability necessary for tissue repair becomes more challenging. Low transplant survival remains the greatest barrier to stem cell-mediated repair of the CNS, often with fewer than 1–2% of the transplanted cells remaining after 1 week. Strategic transplantation parameters, such as injection location, cell concentration, and transplant timing achieve only modest improvements in stem cell transplant survival and appear inconsistent across studies. Biomaterials provide researchers with a means to significantly improve stem cell transplant survival through two mechanisms: (1) a vehicle to deliver and protect the stem cells and (2) a substrate to control the cytotoxic injury environment. These biomaterial strategies can alleviate cell death associated with delivery to the injury and can be used to limit cell death after transplantation by limiting cell exposure to cytotoxic signals. Moreover, it is likely that control of the injury environment with biomaterials will lead to a more reliable support for transplanted cell populations. This review will highlight the challenges associated with cell delivery in the CNS and the advances in biomaterial development and deployment for stem cell therapies necessary to bolster stem cell-mediated repair.

scholarly journals Cerebellar Neurocysticercosis as Long-Term Complication of Allogeneic Haematopoietic Stem Cell Transplantation from Haploidentical Donor

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Federico Meconi ◽  
Giulia Ciangola ◽  
Benedetta Mariotti ◽  
Raffaella Cerretti ◽  
Laura Cudillo ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Taenia Solium ◽  
Haematopoietic Stem Cell ◽  
The Central Nervous System

Neurocysticercosis, an infection of the central nervous system with the larval stage of the cestode Taenia solium, is uncommon in developed countries. We report a case of allogeneic haematopoietic stem cell transplantation from a haploidentical donor complicated, in the long term, by T. solium infection of the central nervous system and successfully treated with empiric antiparasitic therapy with albendazole plus dexamethasone. Revised diagnostic criteria proposed by Del Brutto et al. were used for the definitive diagnosis of cerebellar neurocysticercosis.

scholarly journals Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder

2018 ◽  
Vol 11 (1) ◽  
pp. e226666 ◽  
Author(s):  
Brianne J Sullivan ◽  
Grace J Kim ◽  
Gabriel Sara
Keyword(s):  
Monoclonal Antibody ◽  
Stem Cell ◽  
Lymphoproliferative Disorder ◽  
Stem Cell Transplant ◽  
Bowel Perforation ◽  
Standard Of Care ◽  
Haematopoietic Stem Cell ◽  
Cell Transplant ◽  
Tumour Lysis ◽  
Post Transplant

Post-transplant lymphoproliferative disorder (PTLD) is a recognised complication of solid and haematopoietic stem cell transplant. It consists of a heterogeneous group of lymphoid neoplasms that arises secondary to post-transplant immunosuppression. Although there is no definite standard of care for the optimal treatment for PTLD, rituximab, a monoclonal antibody, with and/or without chemotherapy (usually CHOP=cytoxan, doxorubicin, vincristine, prednisone) has become a routine part of the treatment of any CD20 (+) PTLD, with response rates similar to chemotherapy with decreased toxicity. A rare and often lethal, complication of rituximab therapy for PTLD is bowel perforation secondary to tumour lysis of lymphoma involving the intestine. A small number of cases of bowel perforation have been reported, with very few documented survivors. The risk for recurrent perforation in the setting of ongoing rituximab treatment is unknown. There is sparse data supporting how to best treat the survivors.

Sign in / Sign up

Export Citation Format

Share Document